Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2017 | Aug. 14, 2017 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q2 | |
Entity Registrant Name | AMERICAN BIO MEDICA CORP | |
Entity Central Index Key | 896,747 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | ABMC | |
Entity Common Stock, Shares Outstanding | 29,297,333 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) | Jun. 30, 2017 | Dec. 31, 2016 |
Current assets | ||
Cash and cash equivalents | $ 138,000 | $ 156,000 |
Accounts receivable, net of allowance for doubtful accounts of $49,000 at June 30, 2017 and December 31, 2016 | 482,000 | 556,000 |
Inventory, net of allowance of $468,000 at June 30, 2017 and $449,000 at December 31, 2016 | 1,450,000 | 1,582,000 |
Prepaid expenses and other current assets | 88,000 | 92,000 |
Total current assets | 2,158,000 | 2,386,000 |
Property, plant and equipment, net | 823,000 | 824,000 |
Patents, net | 102,000 | 93,000 |
Other assets | 21,000 | 21,000 |
Deferred finance costs - line of credit, net | 31,000 | 47,000 |
Total assets | 3,135,000 | 3,371,000 |
Current liabilities | ||
Accounts payable | 278,000 | 304,000 |
Accrued expenses and other current liabilities | 263,000 | 276,000 |
Wages payable | 268,000 | 299,000 |
Line of credit | 594,000 | 639,000 |
Current portion of long-term debt | 87,000 | 75,000 |
Total current liabilities | 1,490,000 | 1,593,000 |
Long-term debt, net of current portion and deferred finance costs | 725,000 | 753,000 |
Other long-term liabilities | 25,000 | 0 |
Total liabilities | 2,240,000 | 2,346,000 |
COMMITMENTS AND CONTINGENCIES | ||
Stockholders' equity: | ||
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at June 30, 2017 and December 31, 2016 | 0 | 0 |
Common stock; par value $.01 per share; 50,000,000 shares authorized; 29,297,333 issued and outstanding at June 30, 2017 and 28,842,788 issued and outstanding at December 31, 2016 | 293,000 | 288,000 |
Additional paid-in capital | 21,105,000 | 21,037,000 |
Accumulated deficit | (20,503,000) | (20,300,000) |
Total stockholders’ equity | 895,000 | 1,025,000 |
Total liabilities and stockholders’ equity | $ 3,135,000 | $ 3,371,000 |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2017 | Dec. 31, 2016 |
Allowance For Doubtful Accounts Receivable, Current (in dollars) | $ 49,000 | $ 49,000 |
Inventory Valuation Reserves | $ 468,000 | $ 449,000 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 50,000,000 | 50,000,000 |
Common stock, shares issued | 29,297,333 | 28,842,788 |
Common stock, shares outstanding | 29,297,333 | 28,842,788 |
Condensed Statements of Operati
Condensed Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Net sales | $ 1,306,000 | $ 1,505,000 | $ 2,621,000 | $ 2,975,000 |
Cost of goods sold | 741,000 | 796,000 | 1,491,000 | 1,636,000 |
Gross profit | 565,000 | 709,000 | 1,130,000 | 1,339,000 |
Operating expenses: | ||||
Research and development | 22,000 | 55,000 | 68,000 | 109,000 |
Selling and marketing | 176,000 | 282,000 | 372,000 | 551,000 |
General and administrative | 388,000 | 351,000 | 778,000 | 738,000 |
Operating Expenses, Total | 586,000 | 688,000 | 1,218,000 | 1,398,000 |
Operating loss | (21,000) | 21,000 | (88,000) | (59,000) |
Other income / (expense): | ||||
Interest expense | (69,000) | (71,000) | (134,000) | (138,000) |
Other income, net | 20,000 | 6,000 | 20,000 | 155,000 |
Other income / (expense), Total | (49,000) | (65,000) | (114,000) | 17,000 |
Net loss before tax | (70,000) | (44,000) | (202,000) | (42,000) |
Income tax expense | (1,000) | 0 | (1,000) | (1,000) |
Net loss | $ (71,000) | $ (44,000) | $ (203,000) | $ (43,000) |
Basic and diluted loss per common share (in dollars per share) | $ 0 | $ 0 | $ (0.01) | $ 0 |
Weighted average number of shares outstanding - basic & diluted (in shares) | 29,242,388 | 27,271,408 | 29,043,692 | 26,940,917 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows - USD ($) | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Cash flows from operating activities: | ||
Net loss | $ (203,000) | $ (43,000) |
Adjustments to reconcile net loss to net cash provided by operating activities: | ||
Depreciation and amortization | 43,000 | 46,000 |
Amortization of debt issuance costs | 63,000 | 59,000 |
Provision for slow moving and obsolete inventory | 19,000 | 42,000 |
Share-based payment expense | 23,000 | 36,000 |
Changes in: | ||
Accounts receivable | 74,000 | (48,000) |
Inventory | 113,000 | 93,000 |
Prepaid expenses and other current assets | 54,000 | 19,000 |
Accounts payable | (26,000) | 3,000 |
Accrued expenses and other current liabilities | (13,000) | (6,000) |
Wages payable | (31,000) | (16,000) |
Net cash provided by operating activities | 116,000 | 185,000 |
Cash flows from investing activities: | ||
Patent application costs | (13,000) | (6,000) |
Purchase of property, plant & equipment | (38,000) | 0 |
Net cash used in investing activities | (51,000) | (6,000) |
Cash flows from financing activities: | ||
Proceeds (payments) on debt financing | (38,000) | (75,000) |
Proceeds from lines of credit | 2,835,000 | 3,095,000 |
Payments on lines of credit | (2,880,000) | (3,179,000) |
Net cash (used in) financing activities | (83,000) | (159,000) |
Net (decrease in) / increase in cash and cash equivalents | (18,000) | 20,000 |
Cash and cash equivalents - beginning of period | 156,000 | 158,000 |
Cash and cash equivalents - end of period | 138,000 | 178,000 |
Supplemental disclosures of cash flow information | ||
Cash paid during period for interest | 71,000 | 79,000 |
Cash paid during period for taxes | 1,000 | 1,000 |
Consulting expense prepaid with restricted stock | 50,000 | 49,000 |
Debt issuance cost paid with restricted stock | $ 0 | $ 96,000 |
Basis of Reporting
Basis of Reporting | 6 Months Ended |
Jun. 30, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Accounting [Text Block] | Note A - Basis of Reporting The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at June 30, 2017, the results of operations for the three and six month periods ended June 30, 2017 and June 30, 2016 and, cash flows for the six month periods ended June 30, 2017 and June 30, 2016. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of results that may be expected for the year ending December 31, 2017. Amounts at December 31, 2016 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. During the six months ended June 30, 2017, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, our current cash balances, together with cash generated from future operations and amounts available under our credit facilities may not be sufficient to fund operations through August 2018. On May 1, 2017, we extended our line of credit. The new expiration date of our line of credit is June 29, 2020 1,500,000 ASU 2015-11, “Simplifying the Measurement of Inventory”. ASU 2015-11 was issued in July 2015. ASU 2015-11 applies to inventory measured using the first-in, first-out (“FIFO”) or average cost methods. Under the updated guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company adopted ASU 2015-11 in the quarter ended March 31, 2017, and it did not have a material impact on our financial position or results of operations. ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting”. ASU 2016-09 was issued in March 2016 and it simplifies several aspects of accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods. Early adoption is permitted. An entity that elects early adoption of the amendment under ASU 2016-09 must adopt all aspects of the amendment in the same period. The Company adopted ASU 2016-09 in the quarter ended March 31, 2017 and it did not have a material effect on our financial position or results of operations. ASU 2015-17, “Income Taxes”. ASU 2015-17 was issued in December 2015 and addresses simplification of the presentation of deferred income taxes. The amendments in ASU 2015-17 require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement is that deferred tax liabilities and assets, net of a tax-paying component of an entity be offset and presented as two amounts; one current and one long-term. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption was permitted. The Company adopted ASU 2015-17 in the quarter ended March 31, 2017 and it did not have a material impact on our financial position or results of operations. Accounting Standards Issued; Not Yet Adopted ASU 2017-09, “Compensation Stock Compensation (Topic 718)”. ASU 2017-09 was issued in May 2017. The amendment in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. More specifically, that an entity should account for the effects of modification unless all the following are met: 1) the fair value, calculated or intrinsic value of the modified award is the same fair value, calculated or intrinsic value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original grant is modified. The current disclosure requirements in Topic 718 apply regardless of whether accounting modification is applied. ASU 2017-09 is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is in the process of evaluating the impact of ASU 2017-09. ASU 2017-07, “Compensation - Retirement Benefits” . ASU 2017-07 was issued in March 2017. The amendments in ASU 2017-07 require an employer to report the service cost component of pension and postretirement benefits in the same line item or items as other compensation costs. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside of a subtotal of income from operations. In addition, only the service cost component will be eligible for capitalization as applicable following labor. ASU 2017-07 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of an annual period for which financial statements have not been issued or made available for issuance. The Company is in the process of evaluating the impact of ASU 2017-07. ASU 2017-04, “Intangibles Goodwill and Other (Topic 350)”. ASU 2017-04 was issued in January 2017. The amendments in ASU 2017-04 indicate that an entity will no longer perform a hypothetical purchase price allocation to measure impairment, eliminating step 2 of the goodwill impairment test. Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective prospectively for annual and interim periods in fiscal years beginning after December 15, 2019, but early adoption is permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company is in the process of evaluating the impact of ASU 2017-04. ASU 2017-01, “Business Combinations (Topic 805)” . ASU 2017-01 was issued in January 2017. The amendments in ASU 2017-01 clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for interim and annual periods beginning after December 15, 2017 and should be applied prospectively on or after the effective date. The Company is in the process of evaluating the impact of ASU 2017-01. ASU 2016-02, “Leases”. ASU 2016-02 was issued in February 2016 and it requires a lessee to recognize a lease liability and a right-of-use asset on its balance sheet for all leases, including operating leases, with a term greater than 12 months. Lease classification will determine whether a lease is reported as a financing transaction in the income statement and statement of cash flows. ASU 2016-02 does not substantially change lessor accounting, but it does make certain changes related to leases for which collectability of the lease payments is uncertain or there are significant variable payments. Additionally, ASU 2016-02 makes several other targeted amendments including a) revising the definition of lease payments to include fixed payments by the lessee to cover lessor costs related to ownership of the underlying asset such as for property taxes or insurance; b) narrowing the definition of initial direct costs which an entity is permitted to capitalize to include only those incremental costs of a lease that would not have been incurred if the lease had not been obtained; c) requiring seller-lessees in a sale-leaseback transaction to recognize the entire gain from the sale of the underlying asset at the time of sale rather than over the leaseback term; and d) expanding disclosures to provide quantitative and qualitative information about lease transactions. ASU 2016-02 is effective for all annual and interim periods beginning January 1, 2019, and is required to be applied retrospectively to the earliest period presented at the date of initial application, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-02. ASU 2014-09, “Revenue from Contracts with Customers ”. ASU 2014-09 was issued in May 2014 and it provides guidance for revenue recognition. The core principle of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” was issued as a revision to ASU 2014-09. ASU 2015-14 revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09). The Company is currently evaluating the transition methods and the impact of adopting this ASU. There are no other accounting pronouncements issues during the six months ended June 30, 2017 that are expected to have or that could have a significant impact on our financial position or results of operations. Certain items have been reclassified from the prior year to conform to the current year presentation. |
Inventory
Inventory | 6 Months Ended |
Jun. 30, 2017 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | Note B Inventory June 30, 2017 December 31, 2016 Raw Materials $ 1,043,000 $ 1,028,000 Work In Process 393,000 385,000 Finished Goods 482,000 618,000 Allowance for slow moving and obsolete inventory (468,000) (449,000) $ 1,450,000 $ 1,582,000 |
Net Loss Per Common Share
Net Loss Per Common Share | 6 Months Ended |
Jun. 30, 2017 | |
Earnings Per Share [Abstract] | |
Earnings Per Share [Text Block] | Note C Net Loss Per Common Share June 30, 2017 June 30, 2016 Warrants 2,060,000 2,385,000 Options 2,147,000 2,187,000 4,207,000 4,572,000 The number of securities not included in the diluted net loss per share for the three and six months ended June 30, 2017 was 4,207,000, as their effect would have been anti-dilutive due to the net loss in each period. The number of securities not included in the diluted net loss per share for the three and six months ended June 30, 2016 was 4,572,000, as their effect would have been anti-dilutive due to the net loss in each period. |
Litigation_Legal Matters
Litigation/Legal Matters | 6 Months Ended |
Jun. 30, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Matters and Contingencies [Text Block] | Note D Litigation/Legal Matters In February 2017, the Company filed a complaint in the Supreme Court of the State of New York in Columbia County against Premier Biotech Inc., Premier Biotech Labs, LLC and its principals, including its President Todd Bailey, and Peckham Vocational Industries, Inc. (together the “Defendants”). Mr. Bailey formerly served as the Company’s Vice President of Sales and Marketing, and as a sales consultant until December 23, 2016. The complaint seeks preliminary and permanent injunctions and a temporary restraining order against Todd Bailey (for his benefit or the benefit of another party or entity) related to the solicitation of Company customers as well as damages related to any profits and revenues that would result from actions taken by the Defendants related to Company customers. In March 2017, the complaint was moved to the federal court in the Northern District of New York. In April 2017, the Defendants filed a motion to dismiss, to which the Company responded on April 21, 2017. As of the date of this report, the Company is awaiting the courts rulings on the parties’ motions. In addition, from time to time, the Company may be named in legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such litigation cannot be predicted, if we are unsuccessful in defending any such litigation, the resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company. We are aware of no significant litigation loss contingencies for which management believes it is both probable that a liability has been incurred and that the amount of the loss can be reasonably estimated. |
Line of Credit and Debt
Line of Credit and Debt | 6 Months Ended |
Jun. 30, 2017 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | Note E Line of Credit and Debt June 30, 2017 December 31, 2016 Loan and Security Agreement with Cherokee Financial, LLC: 5 year note at an annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid quarterly with first payment being made on May 15, 2015, annual principal reduction payment of $75,000 due each year beginning on February 15, 2016, with a final balloon payment being due on February 15, 2020. Loan is collateralized by a first security interest in building, land and property. $ 1,050,000 $ 1,125,000 Crestmark Line of Credit: Line of credit (with a current termination date of June 22, 2020) with interest payable at a variable rate based on WSJ Prime plus 2% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated in year 2 or after (and prior to natural expiration). Loan is collateralized by first security interest in receivables and inventory. 594,000 639,000 Crestmark Equipment Term Loan: 38 month equipment loan related to the purchase of manufacturing equipment, at an interest rate of WSJ Prime Rate plus 3%; or 7.25% as of the date of this report. 37,000 0 1,681,000 1,764,000 Less debt discount & issuance costs (Cherokee Financial, LLC Loan) (250,000) (297,000) Total debt, net 1,431,000 1,467,000 Current portion 681,000 714,000 Long-term portion, net of current portion $ 750,000 $ 753,000 LOAN AND SECURITY AGREEMENT WITH CHEROKEE FINANCIAL, LLC On March 26, 2015, the Company entered into a LSA with Cherokee Financial, LLC (the “Cherokee LSA”). The purpose of the Cherokee LSA was to refinance, at a better interest rate, the Company’s Series A Debentures and Cantone Asset Management Bridge Loan (both of which matured on February 1, 2015), as well as the Company’s Mortgage Consolidation Loan with First Niagara Bank (“First Niagara”). The loan is collateralized by a first security interest in real estate and machinery and equipment. Under the Cherokee LSA, the Company was provided the sum of $ 1,200,000 5 8 75,000 1 1 The Company issued 1.8 600,000 As placement agent for the transaction, Cantone Research, Inc. (“CRI”) received a 5% cash fee on the $ 1.2 200,000 196,000 The Company received net proceeds of $ 80,000 1,015,000 60,000 19,000 19,000 3,000 4,000 8 511,000 From these net proceeds, in April 2015, the Company also paid $ 15,000 15 689,000 The Company recognized $ 84,000 47,000 91,000 43,000 44,000 47,000 23,000 11,000 As of June 30, 2017, the balance on the Cherokee LSA is $ 1,050,000 800,000 1,125,000 828,000 LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”) On June 29, 2015 (the “Closing Date”), the Company entered into a three Under the LSA, Crestmark is providing the Company with a Line of Credit of up to $ 1,500,000 500,000 The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $350,000 (“Inventory Sub-Cap Limit”), or 100% of the Eligible Accounts Receivable. So long as any obligations are due to Crestmark, the Company must comply with a minimum Tangible Net Worth (“TNW”) Covenant. Under the LSA, as amended, the Company must maintain a TNW of at least $ 650,000 50 If the Company terminates the LSA prior to June 22, 2020, an early exit fee of 2% of the Maximum Amount (plus any additional amounts owed to Crestmark at the time of termination) would be due. In the event of a default of the LSA, which includes but is not limited to, failure of the Company to make any payment when due and non-compliance with the TNW covenant, Crestmark is permitted to charge an Extra Rate. The Extra Rate is the Company’s then current interest rate plus 12.75% per annum. Under the LSA, interest on the Crestmark Line of Credit is at a variable rate based on the Wall Street Journal Prime Rate plus 2% with a floor of 5.25%. 6.25 7,500 In addition to the Loan Fee paid to Crestmark on the Closing Date, the Company had to pay a success fee (i.e. early termination fee) to Imperium in the amount of $ 50,000 75,000 12,000 3,000 50,000 16,000 8,000 The Company recognized $ 50,000 16,000 47,000 16,000 24,000 8,000 23,000 8,000 Given the nature of the administration of the Crestmark Line of Credit, at June 30, 2017, the Company had $ 0 0 As of June 30, 2017, the balance on the Crestmark Line of Credit was $ 594,000 639,000 EQUIPMENT LOAN WITH CRESTMARK On May 1, 2017, the Company entered into term loan with Crestmark in the amount of $ 38,000 3 7.25 37,000 |
Stock Options and Warrants
Stock Options and Warrants | 6 Months Ended |
Jun. 30, 2017 | |
Stockholders Equity Note [Abstract] | |
Stockholders Equity Note Disclosure [Text Block] | NOTE F Stock Options and Warrants The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares. During the three months ended June 30, 2017, the Company issued options to purchase 20,000 40,000 20,000 80,000 Six months ended June 30, 2017 Six months ended June 30, 2016 Aggregate Aggregate Intrinsic Value as of Intrinsic Value as of June 30, Weighted Average Exercise June 30, Shares Weighted Average Exercise Price 2017 Shares Price 2016 Options outstanding at beginning of period 2,107,000 $ 0.13 1,435,000 $ 0.14 Granted 40,000 $ 0.13 830,000 $ 0.11 Exercised 0 NA 0 NA Cancelled/expired 0 NA (78,000) $ 0.18 Options outstanding at end of period 2,147,000 $ 0.13 $ 15,000 2,187,000 $ 0.13 $ 16,000 Options exercisable at end of period 1,647,000 $ 0.13 1,189,000 $ 0.14 Six months ended 2017 2016 Volatility 81% 62% - 66% Expected term (years) 10 years 10 years Risk-free interest rate 2.16% 1.57% - 1.94% Dividend yield 0% 0% The Company recognized $ 23,000 36,000 11,000 17,000 26,000 6 11 Warrants Six months ended June 30, 2017 Six months ended June 30, 2016 Aggregate Intrinsic Value as of June 30, Aggregate Intrinsic Value as of Shares Weighted Average Exercise Price 2017 Shares Weighted Average Exercise Price June 30, 2016 Warrants outstanding at beginning of period 2,060,000 $ 0.18 2,385,000 $ 0.17 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired 0 NA 0 NA Warrants outstanding at end of period 2,060,000 $ 0.18 None 2,385,000 $ 0.17 $ 0 Warrants exercisable at end of period 2,060,000 $ 0.18 2,385,000 $ 0.17 In the six months ended June 30, 2017 and June 30, 2016, the Company recognized $ 0 0 0 |
SUBSEQUENT EVENT
SUBSEQUENT EVENT | 6 Months Ended |
Jun. 30, 2017 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE G SUBSEQUENT EVENT On July 10, 2017, the Company was notified that it was not awarded a contract with a state agency for which it has held a contract in excess of 10 10 15 |
Basis of Reporting (Policies)
Basis of Reporting (Policies) | 6 Months Ended |
Jun. 30, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards ASU 2015-11, “Simplifying the Measurement of Inventory”. ASU 2015-11 was issued in July 2015. ASU 2015-11 applies to inventory measured using the first-in, first-out (“FIFO”) or average cost methods. Under the updated guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company adopted ASU 2015-11 in the quarter ended March 31, 2017, and it did not have a material impact on our financial position or results of operations. ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting”. ASU 2016-09 was issued in March 2016 and it simplifies several aspects of accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods. Early adoption is permitted. An entity that elects early adoption of the amendment under ASU 2016-09 must adopt all aspects of the amendment in the same period. The Company adopted ASU 2016-09 in the quarter ended March 31, 2017 and it did not have a material effect on our financial position or results of operations. ASU 2015-17, “Income Taxes”. ASU 2015-17 was issued in December 2015 and addresses simplification of the presentation of deferred income taxes. The amendments in ASU 2015-17 require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement is that deferred tax liabilities and assets, net of a tax-paying component of an entity be offset and presented as two amounts; one current and one long-term. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption was permitted. The Company adopted ASU 2015-17 in the quarter ended March 31, 2017 and it did not have a material impact on our financial position or results of operations. Accounting Standards Issued; Not Yet Adopted ASU 2017-09, “Compensation Stock Compensation (Topic 718)”. ASU 2017-09 was issued in May 2017. The amendment in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. More specifically, that an entity should account for the effects of modification unless all the following are met: 1) the fair value, calculated or intrinsic value of the modified award is the same fair value, calculated or intrinsic value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original grant is modified. The current disclosure requirements in Topic 718 apply regardless of whether accounting modification is applied. ASU 2017-09 is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is in the process of evaluating the impact of ASU 2017-09. ASU 2017-07, “Compensation - Retirement Benefits” . ASU 2017-07 was issued in March 2017. The amendments in ASU 2017-07 require an employer to report the service cost component of pension and postretirement benefits in the same line item or items as other compensation costs. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside of a subtotal of income from operations. In addition, only the service cost component will be eligible for capitalization as applicable following labor. ASU 2017-07 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of an annual period for which financial statements have not been issued or made available for issuance. The Company is in the process of evaluating the impact of ASU 2017-07. ASU 2017-04, “Intangibles Goodwill and Other (Topic 350)”. ASU 2017-04 was issued in January 2017. The amendments in ASU 2017-04 indicate that an entity will no longer perform a hypothetical purchase price allocation to measure impairment, eliminating step 2 of the goodwill impairment test. Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective prospectively for annual and interim periods in fiscal years beginning after December 15, 2019, but early adoption is permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company is in the process of evaluating the impact of ASU 2017-04. ASU 2017-01, “Business Combinations (Topic 805)” . ASU 2017-01 was issued in January 2017. The amendments in ASU 2017-01 clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for interim and annual periods beginning after December 15, 2017 and should be applied prospectively on or after the effective date. The Company is in the process of evaluating the impact of ASU 2017-01. ASU 2016-02, “Leases”. ASU 2016-02 was issued in February 2016 and it requires a lessee to recognize a lease liability and a right-of-use asset on its balance sheet for all leases, including operating leases, with a term greater than 12 months. Lease classification will determine whether a lease is reported as a financing transaction in the income statement and statement of cash flows. ASU 2016-02 does not substantially change lessor accounting, but it does make certain changes related to leases for which collectability of the lease payments is uncertain or there are significant variable payments. Additionally, ASU 2016-02 makes several other targeted amendments including a) revising the definition of lease payments to include fixed payments by the lessee to cover lessor costs related to ownership of the underlying asset such as for property taxes or insurance; b) narrowing the definition of initial direct costs which an entity is permitted to capitalize to include only those incremental costs of a lease that would not have been incurred if the lease had not been obtained; c) requiring seller-lessees in a sale-leaseback transaction to recognize the entire gain from the sale of the underlying asset at the time of sale rather than over the leaseback term; and d) expanding disclosures to provide quantitative and qualitative information about lease transactions. ASU 2016-02 is effective for all annual and interim periods beginning January 1, 2019, and is required to be applied retrospectively to the earliest period presented at the date of initial application, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-02. ASU 2014-09, “Revenue from Contracts with Customers ”. ASU 2014-09 was issued in May 2014 and it provides guidance for revenue recognition. The core principle of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” was issued as a revision to ASU 2014-09. ASU 2015-14 revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09). The Company is currently evaluating the transition methods and the impact of adopting this ASU. There are no other accounting pronouncements issues during the six months ended June 30, 2017 that are expected to have or that could have a significant impact on our financial position or results of operations. |
Reclassification, Policy [Policy Text Block] | Reclassifications Certain items have been reclassified from the prior year to conform to the current year presentation. |
Inventory (Tables)
Inventory (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | Inventory is comprised of the following: June 30, 2017 December 31, 2016 Raw Materials $ 1,043,000 $ 1,028,000 Work In Process 393,000 385,000 Finished Goods 482,000 618,000 Allowance for slow moving and obsolete inventory (468,000) (449,000) $ 1,450,000 $ 1,582,000 |
Net Loss Per Common Share (Tabl
Net Loss Per Common Share (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants. June 30, 2017 June 30, 2016 Warrants 2,060,000 2,385,000 Options 2,147,000 2,187,000 4,207,000 4,572,000 |
Line of Credit and Debt (Tables
Line of Credit and Debt (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt Instruments [Table Text Block] | June 30, 2017 December 31, 2016 Loan and Security Agreement with Cherokee Financial, LLC: 5 year note at an annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid quarterly with first payment being made on May 15, 2015, annual principal reduction payment of $75,000 due each year beginning on February 15, 2016, with a final balloon payment being due on February 15, 2020. Loan is collateralized by a first security interest in building, land and property. $ 1,050,000 $ 1,125,000 Crestmark Line of Credit: Line of credit (with a current termination date of June 22, 2020) with interest payable at a variable rate based on WSJ Prime plus 2% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated in year 2 or after (and prior to natural expiration). Loan is collateralized by first security interest in receivables and inventory. 594,000 639,000 Crestmark Equipment Term Loan: 38 month equipment loan related to the purchase of manufacturing equipment, at an interest rate of WSJ Prime Rate plus 3%; or 7.25% as of the date of this report. 37,000 0 1,681,000 1,764,000 Less debt discount & issuance costs (Cherokee Financial, LLC Loan) (250,000) (297,000) Total debt, net 1,431,000 1,467,000 Current portion 681,000 714,000 Long-term portion, net of current portion $ 750,000 $ 753,000 |
Stock Options and Warrants (Tab
Stock Options and Warrants (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the six months ended June 30, 2017 and June 30, 2016: Six months ended 2017 2016 Volatility 81% 62% - 66% Expected term (years) 10 years 10 years Risk-free interest rate 2.16% 1.57% - 1.94% Dividend yield 0% 0% |
Warrant [Member] | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Warrant activity for the six months ended June 30, 2017 and June 30, 2016 is summarized as follows: Six months ended June 30, 2017 Six months ended June 30, 2016 Aggregate Intrinsic Value as of June 30, Aggregate Intrinsic Value as of Shares Weighted Average Exercise Price 2017 Shares Weighted Average Exercise Price June 30, 2016 Warrants outstanding at beginning of period 2,060,000 $ 0.18 2,385,000 $ 0.17 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired 0 NA 0 NA Warrants outstanding at end of period 2,060,000 $ 0.18 None 2,385,000 $ 0.17 $ 0 Warrants exercisable at end of period 2,060,000 $ 0.18 2,385,000 $ 0.17 |
Employee Stock Option [Member] | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Stock option activity for the six months ended June 30, 2017 and June 30, 2016 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand): Six months ended June 30, 2017 Six months ended June 30, 2016 Aggregate Aggregate Intrinsic Value as of Intrinsic Value as of June 30, Weighted Average Exercise June 30, Shares Weighted Average Exercise Price 2017 Shares Price 2016 Options outstanding at beginning of period 2,107,000 $ 0.13 1,435,000 $ 0.14 Granted 40,000 $ 0.13 830,000 $ 0.11 Exercised 0 NA 0 NA Cancelled/expired 0 NA (78,000) $ 0.18 Options outstanding at end of period 2,147,000 $ 0.13 $ 15,000 2,187,000 $ 0.13 $ 16,000 Options exercisable at end of period 1,647,000 $ 0.13 1,189,000 $ 0.14 |
Basis of Reporting (Details Tex
Basis of Reporting (Details Textual) - Crestmark Bank [Member] - USD ($) | May 01, 2017 | Jun. 30, 2017 |
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,500,000 | $ 1,500,000 |
Line of Credit Facility, Expiration Date | Jun. 29, 2020 |
Inventory (Details)
Inventory (Details) - USD ($) | Jun. 30, 2017 | Dec. 31, 2016 |
Inventory [Line Items] | ||
Raw Materials | $ 1,043,000 | $ 1,028,000 |
Work In Process | 393,000 | 385,000 |
Finished Goods | 482,000 | 618,000 |
Allowance for slow moving and obsolete inventory | (468,000) | (449,000) |
Inventory, Net, Total | $ 1,450,000 | $ 1,582,000 |
Net Loss Per Common Share (Deta
Net Loss Per Common Share (Details) - shares | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Weighted Average Number Diluted Shares Outstanding Adjustment | 4,207,000 | 4,572,000 |
Warrant [Member] | ||
Weighted Average Number Diluted Shares Outstanding Adjustment | 2,060,000 | 2,385,000 |
Employee Stock Option [Member] | ||
Weighted Average Number Diluted Shares Outstanding Adjustment | 2,147,000 | 2,187,000 |
Net Loss Per Common Share (De21
Net Loss Per Common Share (Details Textual) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 4,207,000 | 4,572,000 | 4,207,000 | 4,572,000 |
Line of Credit and Debt (Detail
Line of Credit and Debt (Details) - USD ($) | Jun. 30, 2017 | Dec. 31, 2016 |
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | $ 1,681,000 | $ 1,764,000 |
Less debt discount & issuance costs (Cherokee Financial, LLC Loan) | (250,000) | (297,000) |
Total debt, net | 1,431,000 | 1,467,000 |
Current portion | 681,000 | 714,000 |
Long-term portion, net of current portion | 725,000 | 753,000 |
Cherokee Financial LLC [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | 1,050,000 | 1,125,000 |
Crestmark Line of Credit [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | 594,000 | 639,000 |
Crestmark Equipment Term Loan [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | $ 37,000 | $ 0 |
Line of Credit and Debt (Deta23
Line of Credit and Debt (Details Textual) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Line of Credit Facility [Line Items] | |
Line of Credit Facility, Description | annual interest rate of 8% plus a 1% annual oversight fee, |
Cherokee Financial LLC [Member] | |
Line of Credit Facility [Line Items] | |
Debt Instrument, Maturity Date | May 15, 2015 |
Debt Instrument, Term | 5 years |
Line of Credit Facility, Interest Rate Description | annual interest rate of 8% plus a 1% annual oversight fee, |
Line of Credit Facility, Periodic Payment, Principal | $ 75,000 |
Crestmark Line of Credit [Member] | |
Line of Credit Facility [Line Items] | |
Debt Instrument, Term | 3 years |
Line of Credit Facility, Interest Rate Description | WSJ Prime plus 2% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated in year 2 or after (and prior to natural expiration). |
Line of Credit and Debt - Loan
Line of Credit and Debt - Loan and Security Agreement With Cherokee Financial, LLC (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||
Apr. 30, 2015 | Jun. 30, 2017 | Jun. 30, 2016 | Mar. 31, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | May 01, 2017 | Dec. 31, 2016 | Mar. 25, 2015 | |
Line of Credit Facility [Line Items] | |||||||||
Debt Related Commitment Fees and Debt Issuance Costs | $ 0 | $ 0 | $ 0 | $ 0 | |||||
Debt Instrument, Face Amount | $ 38,000 | ||||||||
Interest Expense, Debt | 0 | ||||||||
Debt Instrument, Unamortized Discount | $ 800,000 | $ 800,000 | $ 828,000 | ||||||
Crestmark Equipment Term Loan [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Debt Instrument, Description of Variable Rate Basis | Prime Rate plus 3%; or 7.25% | ||||||||
Cherokee Financial LLC [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Debt Related Commitment Fees and Debt Issuance Costs | $ 47,000 | 23,000 | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||||
Debt Instrument, Face Amount | $ 1,200,000 | $ 1,200,000 | |||||||
Interest Expense, Debt | 11,000 | 47,000 | |||||||
Notes and Loans, Noncurrent | 1,050,000 | $ 1,050,000 | $ 1,125,000 | ||||||
Annual Fee Percentage | 1.00% | ||||||||
Debt Instrument, Annual Principal Payment | 75,000 | $ 75,000 | |||||||
Debt Instrument, Term | 5 years | ||||||||
Administrative Fees Percentage | 1.00% | ||||||||
Cherokee Financial LLC [Member] | Final Balloon [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Debt Instrument, Maturity Date | Mar. 26, 2020 | ||||||||
Cherokee Loan and Security Agreement [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 200,000 | ||||||||
Placement Agent Fees | $ 60,000 | ||||||||
Proceeds from Debt, Net of Issuance Costs | 80,000 | ||||||||
Repayments of Debt | 1,015,000 | ||||||||
Legal Fees | 19,000 | ||||||||
Debt Related Commitment Fees and Debt Issuance Costs | 19,000 | ||||||||
State Filing Fees | 3,000 | ||||||||
Interest Expense, Debt | 44,000 | $ 91,000 | 84,000 | $ 43,000 | |||||
Notes and Loans, Noncurrent | $ 1,200,000 | 1,200,000 | |||||||
Cherokee Loan and Security Agreement [Member] | New Participations [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Debt Instrument, Periodic Payment, Interest | $ 4,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||
Debt Instrument, Face Amount | $ 511,000 | ||||||||
Cherokee Loan and Security Agreement [Member] | Series A Debentures and CAM Bridge Loan [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Debt Instrument, Periodic Payment, Interest | $ 15,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 15.00% | ||||||||
Debt Instrument, Face Amount | $ 689,000 | ||||||||
Cherokee Loan and Security Agreement [Member] | Cherokee Financial LLC [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Contingent Consideration Additional Restricted Shares Issuable | 600,000 | ||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 1,800,000 | ||||||||
Cherokee Loan and Security Agreement [Member] | Cantone Research Inc [Member] | New Participations [Member] | |||||||||
Line of Credit Facility [Line Items] | |||||||||
Contingent Consideration Additional Restricted Shares Issuable | 196,000 |
Line of Credit and Debt - Line
Line of Credit and Debt - Line of Credit with Crestmark Bank ("Crestmark") (Details Textual) - USD ($) | May 01, 2017 | Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 | Jun. 29, 2015 |
Line of Credit Facility [Line Items] | |||||||
Line of Credit Facility, Interest Rate During Period | 6.25% | ||||||
Debt Related Commitment Fees and Debt Issuance Costs | $ 0 | $ 0 | $ 0 | $ 0 | |||
Interest Expense, Debt | 0 | ||||||
Debt Instrument, Face Amount | $ 38,000 | ||||||
Amortization of debt issuance costs | 63,000 | 59,000 | |||||
Long-term Debt, Gross | 1,681,000 | 1,681,000 | $ 1,764,000 | ||||
Interest Expense [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Amortization of debt issuance costs | 8,000 | ||||||
Interest Expense One [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Amortization of debt issuance costs | 8,000 | ||||||
Imperium Line Of Credit [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest Expense, Debt | 0 | ||||||
Line Of Credit Facility Termination Fee | $ 50,000 | ||||||
Minimum [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 3.00% | ||||||
Maximum [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 7.25% | ||||||
Crestmark Bank [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,500,000 | 1,500,000 | 1,500,000 | ||||
Minimum Loan Balance | 500,000 | $ 500,000 | |||||
Debt Instrument, Fee | 75,000 | ||||||
Debt Instrument, Fee Amount | 594,000 | $ 594,000 | $ 639,000 | ||||
Interest Expense, Debt | 24,000 | $ 23,000 | 50,000 | ||||
Amortization of debt issuance costs | 16,000 | $ 16,000 | |||||
Line of Credit Facility, Expiration Date | Jun. 29, 2020 | ||||||
Long-term Debt, Gross | 37,000 | $ 37,000 | |||||
Crestmark Bank [Member] | Minimum [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Line of Credit Facility, Expiration Date | Jun. 22, 2018 | ||||||
Crestmark Bank [Member] | Maximum [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Line of Credit Facility, Expiration Date | Jun. 22, 2020 | ||||||
Imperium [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt Instrument, Fee Amount | 50,000 | $ 50,000 | |||||
Crestmark Loan And Security Agreeement [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Minimum Net Worth Required for Compliance | $ 650,000 | 650,000 | |||||
Debt Related Commitment Fees and Debt Issuance Costs | $ 16,000 | ||||||
Crestmark Loan And Security Agreeement [Member] | Crestmark Bank [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Line of Credit Facility, Borrowing Capacity, Description | The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $350,000 (“Inventory Sub-Cap Limit”), or 100% of the Eligible Accounts Receivable. | ||||||
Debt Instrument, Fee | the Company will pay Crestmark a Loan Fee of 0.50%, or $7,500, and a Monthly Maintenance Fee of 0.30% of the actual average monthly loan balance from the prior month will be paid to Crestmark. | ||||||
Debt Instrument, Debt Default, Description of Violation or Event of Default | The Extra Rate is the Company’s then current interest rate plus 12.75% per annum. | ||||||
Line of Credit Facility, Interest Rate Description | variable rate based on the Wall Street Journal Prime Rate plus 2% with a floor of 5.25%. | ||||||
Payments of Debt Issuance Costs | $ 12,000 | ||||||
Legal Fees | $ 3,000 | ||||||
Percentage of Net Income, Increase | 50.00% | 50.00% | |||||
Weighted Average Annual Fee | $ 7,500 | ||||||
Crestmark Loan And Security Agreeement [Member] | Crestmark Bank [Member] | Prime Rate [Member] | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt Instrument, Interest Rate, Increase (Decrease) | 0.25% |
Stock Options and Warrants (Det
Stock Options and Warrants (Details) - Employee Stock Option [Member] - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Shares, Beginning Balance | 2,107,000 | 1,435,000 | ||
Shares, Granted | 40,000 | 80,000 | 40,000 | 830,000 |
Shares, Exercised | 0 | 0 | ||
Shares, Cancelled/expired | 0 | (78,000) | ||
Shares, Ending Balance | 2,147,000 | 2,187,000 | 2,147,000 | 2,187,000 |
Exercisable at end of period | 1,647,000 | 1,189,000 | 1,647,000 | 1,189,000 |
Weighted Average Exercise Price, at beginning of period | $ 0.13 | $ 0.14 | ||
Weighted Average Exercise Price, Granted | 0.13 | 0.11 | ||
Weighted Average Exercise Price, Cancelled/expired | 0 | 0.18 | ||
Weighted Average Exercise Price, at end of period | $ 0.13 | $ 0.13 | 0.13 | 0.13 |
Weighted Average Exercise Price, Exercisable, at end of period | $ 0.13 | $ 0.14 | $ 0.13 | $ 0.14 |
Aggregate Intrinsic Value, Outstanding at end of period | $ 15,000 | $ 16,000 | $ 15,000 | $ 16,000 |
Stock Options and Warrants (D27
Stock Options and Warrants (Details 1) | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 81.00% | |
Expected term (years) | 10 years | 10 years |
Risk-free interest rate | 2.16% | |
Dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 62.00% | |
Risk-free interest rate | 1.57% | |
Maximum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 66.00% | |
Risk-free interest rate | 1.94% |
Stock Options and Warrants (D28
Stock Options and Warrants (Details 2) - Warrant [Member] | 6 Months Ended | |
Jun. 30, 2017$ / sharesshares | Jun. 30, 2016USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Shares, Beginning Balance | 2,060,000 | 2,385,000 |
Shares, Granted | 0 | 0 |
Shares, Exercised | 0 | 0 |
Shares, Cancelled/expired | 0 | 0 |
Shares, Ending Balance | 2,060,000 | 2,385,000 |
Exercisable at end of period | 2,060,000 | 2,385,000 |
Weighted Average Exercise Price, at beginning of period | $ / shares | $ 0.18 | $ 0.17 |
Weighted Average Exercise Price, Cancelled/expired | $ / shares | 0 | 0 |
Weighted Average Exercise Price, at end of period | $ / shares | 0.18 | 0.17 |
Weighted Average Exercise Price, Exercisable, at end of period | $ / shares | $ 0.18 | $ 0.17 |
Aggregate Intrinsic Value outstanding at period | $ | $ 0 |
Stock Options and Warrants (D29
Stock Options and Warrants (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 0 | $ 0 | ||
Debt Related Commitment Fees and Debt Issuance Costs | 0 | $ 0 | 0 | $ 0 |
Allocated Share-based Compensation Expense | $ 11,000 | $ 17,000 | $ 23,000 | $ 36,000 |
Non-Employee Board One [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 20,000 | |||
Non-Employee Board Two [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 20,000 | |||
Non-Employee Board Three [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 20,000 | |||
Non-Employee Board Four [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 20,000 | |||
Employee Stock Option [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 40,000 | 80,000 | 40,000 | 830,000 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 26,000 | $ 26,000 | ||
Employee Stock Option [Member] | Chief Executive Officer [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 20,000 | |||
Employee Stock Option [Member] | Minimum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 6 months | |||
Employee Stock Option [Member] | Maximum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 11 months |
SUBSEQUENT EVENT (Details Texua
SUBSEQUENT EVENT (Details Texual) - Subsequent Event [Member] | Jul. 10, 2017 |
Subsequent Event [Line Items] | |
Term Of Contract | 10 years |
Maximum [Member] | |
Subsequent Event [Line Items] | |
Contract Revenue Percentage In Total Revenue | 15.00% |
Minimum [Member] | |
Subsequent Event [Line Items] | |
Contract Revenue Percentage In Total Revenue | 10.00% |